London Daily

Focus on the big picture.
Wednesday, Jul 16, 2025

Oxford Covid vaccine 'safe and effective' study shows

Oxford Covid vaccine 'safe and effective' study shows

The Oxford/AstraZeneca Covid vaccine is safe and effective, giving good protection, researchers have confirmed in The Lancet journal.

Most in the study were younger than 55, but the results so far indicate it does work well in older people too.

The data also suggest it can reduce spread of Covid, as well as protect against illness and death.

The paper, assessed by independent scientists, sets out full results from advanced trials of over 20,000 people.

Regulators, who will have seen the same data, are considering the jab for emergency use.

But there are still important questions about what dose to give, as well as who it will protect.

When the interim trial results were made public in a press release about a fortnight ago, the researchers reported three efficacy levels for the vaccine - an overall effectiveness of 70%, a lower one of 62% and a high of 90%.

That's because different doses of the vaccine were used in one part of the trial. Some volunteers were given shots that were half the strength than originally planned.
Yet that "wrong" dose turned out to be a winner - giving 90% protection - while two standard doses gave 62%.

The Lancet report reveals 1,367 people - out of many thousands in the trial - received the half dose followed by a full dose, which gave them 90% protection against getting ill with Covid-19.

The relatively small numbers means it is hard to draw firm conclusions.

None of that group were over the age of 55 though - and experts know it is older people who are most at risk of severe Covid illness.

In terms of safety, there was one severe adverse event potentially related to the vaccine and another one - a high temperature - that is still being investigated.

Both these participants are recovering and are still in the trial.

The study also measured protection against asymptomatic infection by asking volunteers to do regular swabs to check if they had Covid without feeling unwell.

More of these cases were seen in the group that did not receive the vaccine.

Pascal Soriot, chief executive officer for AstraZeneca said: "The results show that the vaccine is effective against Covid-19, with in particular no severe infections and no hospitalisations in the vaccine group, as well as safe and well tolerated.

"We have begun submitting data to regulatory authorities around the world for early approval and our global supply chains are up and running, ready to quickly begin delivering hundreds of millions of doses on a global scale at no profit."

Dr Charlie Weller, Head of Vaccines at Wellcome, said: "Today marks another key milestone in the Covid-19 vaccine journey.

"Although we await the trial completion and full data, it is highly encouraging to see the data behind the interim results announced last month, including an analysis of the different dosing regimens. This suggests that this vaccine could prevent asymptomatic disease."

AstraZeneca executive vice-president Sir Mene Pangalos said adults of all ages needed to be vaccinated to make a "dent" in the pandemic.

"I realise the people that are most severely impacted by disease are the over-65s, over-75s, over-85s, but the reality is we need to actually have vaccines that immunise everyone from adolescence to the oldest adults to really dent the pandemic around the world," he said.

Meanwhile, the UK has started a mass vaccination campaign with another Covid jab made by Pfizer/BioNTech.

On Tuesday Margaret Keenan, a 91-year-old grandmother, became the first person in the world to get the Pfizer Covid-19 jab as part of a mass vaccination programme..

The Oxford/AstraZeneca vaccine could also play a major role in fighting the pandemic if it is approved soon.

It is cheaper than some of the other Covid vaccines and easier to store and distribute.



The UK government has pre-ordered 100 million doses of the Oxford vaccine, which uses a harmless virus altered to look a lot more like the virus that causes Covid-19.

AstraZeneca says it will make three billion doses for the world next year.


Laura Foster explains why the Oxford vaccine matters


Newsletter

Related Articles

0:00
0:00
Close
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Defends Attorney General Pam Bondi Amid Epstein Memo Backlash
Renault Shares Drop as CEO Luca de Meo Announces Departure Amid Reports of Move to Kering
Senior Aides for King Charles and Prince Harry Hold Secret Peace Summit
Anti‑Semitism ‘Normalised’ in Middle‑Class Britain, Says Commission Co‑Chair
King Charles Meets David Beckham at Chelsea Flower Show
If the Department is Really About Justice: Ghislaine Maxwell Should Be Freed Now
NYC Candidate Zohran Mamdani’s ‘Antifada’ Remarks Spark National Debate on Political Language and Economic Policy
President Trump Visits Flood-Ravaged Texas, Praises Community Strength and First Responders
From Mystery to Meltdown, Crisis Within the Trump Administration: Epstein Files Ignite A Deepening Rift at the Highest Levels of Government Reveals Chaos, Leaks, and Growing MAGA Backlash
Trump Slams Putin Over War Death Toll, Teases Major Russia Announcement
Reparations argument crushed
Rainmaker CEO Says Cloud Seeding Paused Before Deadly Texas Floods
A 92-year-old woman, who felt she doesn't belong in a nursing home, escaped the death-camp by climbing a gate nearly 8 ft tall
French Journalist Acquitted in Controversial Case Involving Brigitte Macron
Elon Musk’s xAI Targets $200 Billion Valuation in New Fundraising Round
Kraft Heinz Considers Splitting Off Grocery Division Amid Strategic Review
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
EU Proposes New Tax on Large Companies to Boost Budget
Trump Imposes 35% Tariffs on Canadian Imports Amid Trade Tensions
Junior Doctors in the UK Prepare for Five-Day Strike Over Pay Disputes
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
Bitcoin Reaches New Milestone of $116,000
Biden’s Doctor Pleads the Fifth to Avoid Self-Incrimination on President’s Medical Fitness
Grok Chatbot Faces International Backlash for Antisemitic Content
Severe Heatwave Claims 2,300 Lives Across Europe
NVIDIA Achieves Historic Milestone as First Company Valued at $4 Trillion
Declining Beer Consumption Signals Cultural Shift in Germany
Linda Yaccarino Steps Down as CEO of X After Two Years
×